The content is available as a PDF (363.4 KB).
Footnotes
Disclosure
Financial support: none. Conflicts of interest: none.
References
- 1.Weber MM, Fottner C. Immune checkpoint inhibitors in the treatment of patients with neuroendocrine neoplasia. Oncol Res Treat. 2018;41:306–12. doi: 10.1159/000488996. [DOI] [PubMed] [Google Scholar]
- 2.Sibaud V, Meyer N, Lamant L, Vigarios E, Mazieres J, Delord JP. Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies. Curr Opin Oncol. 2016;28:254–63. doi: 10.1097/CCO.0000000000000290. [DOI] [PubMed] [Google Scholar]
- 3.Baxi S, Yang A, Gennarelli RL, et al. Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis. BMJ. 2018;360:k793. doi: 10.1136/bmj.k793. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Bonigen J, Raynaud-Donzel C, Hureaux J, et al. Anti-PD1-induced psoriasis: a study of 21 patients. JEADV. 2016;31(5):e254–7. doi: 10.1111/jdv.14011. [DOI] [PubMed] [Google Scholar]
- 5.Murata S, Kaneko S, Harada Y, et al. Case of de novo psoriasis possibly triggered by nivolumab. J Dermatol. 2016;44(1):99–100. doi: 10.1111/1346-8138.13450. [DOI] [PubMed] [Google Scholar]
- 6.Ruiz-Bañobre J, Abdulkader I, Anido U, et al. Development of de novo psoriasis during nivolumab therapy for metastatic renal cell carcinoma: immunohistochemical analyses and clinical outcome. APMIS. 2017;125(3):259–63. doi: 10.1111/apm.12658. [DOI] [PubMed] [Google Scholar]
- 7.Ohtsuka M, Miura T, Mori T, Ishikawa M, Yamamoto T. Occurrence of psoriasiform eruption during nivolumab therapy for primary oral mucosal melanoma. JAMA Dermatology. 2015;151(7):797. doi: 10.1001/jamadermatol.2015.0249. [DOI] [PubMed] [Google Scholar]
- 8.Totonchy MB, Ezaldein HH, Ko CJ, et al. Inverse psoriasiform eruption during pembrolizumab therapy for metastatic melanoma. JAMA Dermatology. 2016;152(5):590. doi: 10.1001/jamadermatol.2015.5210. [DOI] [PubMed] [Google Scholar]
- 9.Gordon KB, Blauvelt A, Papp KA, et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Eng J Med. 2016;375(4):345–56. doi: 10.1056/NEJMoa1512711. [DOI] [PubMed] [Google Scholar]
- 10.Johnson D, Patel AB, Uemura MI, Trinh VA, Jackson N, Zobniw CM, et al. IL17A blockade successfully treated psoriasiform dermatologic toxicity from immunotherapy. Cancer Immunol Res. 2019;7(6):860–5. doi: 10.1158/2326-6066.CIR-18-0682. [DOI] [PubMed] [Google Scholar]